SecBot SecBot
8-K ·Filed Nov 5, 2026

PTGX

Protagonist Therapeutics, Inc
BULLISH
Impact 7/10
Horizonweeks Processed11d 10h ago SEC0001104659-26-123351
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The MIMRYLO approval milestone and opt-out payments have transformed Protagonist into a cash-flow-positive, royalty-generating biotech. Watch for ICOTYDE royalty ramp from J&J's global launches and the pace of the $300M buyback execution. PN-881 Phase 2b initiation in early Q1 2027 is the next key pipeline catalyst.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

PTGX drug pipeline →

ICOTYDE

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercially launched in the US (March 2026), EU (September 2026), and UK (October 2026).
Next catalyst
None dated

What to watchICOTYDE is already approved and generating revenue. The next major catalyst would be a regulatory filing for psoriatic arthritis (Phase 3 data just presented at ACR Nov 2026), but no submission or PDUFA date has been announced yet. Watch for J&J's filing plans and quarterly royalty revenue growth as the commercial launch ramps.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$132.04
T+0 close · Nov 5, 2026 · via day close
Latest settled
−0.83%
T+5 · $130.95 · next T+20 in 20d
Vs SPY
−3.42%
α at T+5
Latest observation
−4.60%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $132.04entry
  2. T+1 · 8d ago +2.92%α +0.56% · $135.90
  3. T+5 · 4d ago −0.83%α −3.42% · $130.95
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Protagonist Therapeutics reported Q3 2026 net income of $220.0M ($3.07 diluted EPS) on $274.4M in license and collaboration revenue, driven by $275M in payments from Takeda triggered by FDA approval of MIMRYLO (rusfertide). Results far exceeded consensus EPS of $2.66 and revenue of $241.3M, and the company ended the quarter with $834.6M in cash and a $300M share repurchase program in place.

Key Financial Metrics

EPS
$3.07
est $2.66 · +15.4%
Revenue
$274.4M
est $241.3M · +13.7%
Rating
beat

Key Facts

  • FDA approval of MIMRYLO (rusfertide) triggered $275M in payments to Protagonist in Q3 2026
  • Q3 2026 net income of $220.0M vs net loss of $39.3M in Q3 2025
  • Diluted EPS of $3.07 vs consensus estimate of $2.66 (beat by 15.4%)
  • License and collaboration revenue of $274.4M vs consensus $241.3M (beat by 13.7%)
  • Cash, cash equivalents and marketable securities of $834.6M as of September 30, 2026
  • $300M share repurchase program authorized in September 2026
  • ICOTYDE received regulatory approvals in China, Japan and the EU during Q3 2026
  • PN-881 Phase 1 study completed; Phase 2b planned for early Q1 2027

Financial Impact

Q3 2026 net income of $220.0M vs net loss of $39.3M in Q3 2025; license and collaboration revenue of $274.4M vs $4.7M in Q3 2025

revenueepscash

Risk Factors

  • Revenue is heavily dependent on milestone payments from partners (Takeda, J&J) which are lumpy and non-recurring
  • ICOTYDE and MIMRYLO commercial success depends on partner execution (J&J, Takeda)
  • R&D expenses expected to increase as pipeline programs advance into later-stage trials
  • Share repurchase program timing and amount are discretionary

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-123351
Document: tm2629043d1_8k.htm0001104659-26-123351
Document: 0001104659-26-123351-index-headers.html0001104659-26-123351
Document: 0001104659-26-123351-index.html0001104659-26-123351
Document: 0001104659-26-123351.txt0001104659-26-123351
8-K Data (Synthetic)0001104659-26-123351

Track record

11 reports on PTGX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +31.42% at T+60 after the May 5, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Bullish 7/10 Viewing Entry $132.04 Now $124.83 −5.46% settles Feb 4
  2. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $143.37 Now $124.83 −12.93% settles Feb 2
  3. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $142.14 Now $124.83 −12.18% settles Jan 26
  4. Aug 10, 202614w ago 144 Bearish 5/10 Entry $148.29 to $143.37 Now $124.83 +15.82% ▲ +3.32% +2.83% vs SPY
  5. Jun 18, 202621w ago 8-K Neutral 3/10 Entry $115.03 to $143.40 Now $124.83 +8.52% ▲ +24.66% +22.92% vs SPY
  6. Jun 12, 202622w ago Institutional Cluster Mixed 5/10 Entry $109.78 to $145.94 Now $124.83 +13.71% ▲ +32.94% +29.67% vs SPY
  7. May 12, 202626w ago 144 Bearish 5/10 Entry $103.88 to $145.87 Now $124.83 −20.17% ▼ −40.42% −35.98% vs SPY
  8. May 8, 202627w ago Insider Cluster Neutral 4/10 Entry $99.36 to $135.81 Now $124.83 +25.63% ▲ +36.68% +31.85% vs SPY
  9. May 8, 202627w ago Insider Cluster Neutral 5/10 Entry $99.36 to $135.81 Now $124.83 +25.63% ▲ +36.68% +31.85% vs SPY
  10. May 5, 202627w ago 8-K Bullish 7/10 Entry $103.97 to $136.64 Now $124.83 +20.06% ▲ +31.42% +29.36% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026